Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
Revenues | 19,078.0 | 17,938.0 | 16,663.0 | 34,438.0 | 35,978.0 | 33,558.0 | 31,366.0 | 29,447.0 |
Revenue growth | 6.4% | 7.7% | -51.6% | -4.3% | 7.2% | 7.0% | 6.5% | 7.4% |
Cost of goods sold | 3,702.0 | 3,397.0 | 3,227.0 | 4,847.0 | 4,910.0 | 4,373.0 | 483.0 | 502.0 |
Gross profit | 15,376.0 | 14,541.0 | 13,436.0 | 29,591.0 | 31,068.0 | 29,185.0 | 30,883.0 | 28,945.0 |
Gross margin | 80.6% | 81.1% | 80.6% | 85.9% | 86.4% | 87.0% | 98.5% | 98.3% |
Selling, general and administrative | | | | | | | | |
General and administrative | 1,507.0 | 1,415.0 | 1,353.0 | 1,964.0 | 2,030.0 | 1,961.0 | 1,802.0 | 1,401.0 |
EBITA | 3,313.0 | 2,682.0 | 2,204.0 | 4,405.0 | 3,947.0 | 4,391.0 | 3,164.0 | 4,496.0 |
EBITA margin | 17.4% | 15.0% | 13.2% | 12.8% | 11.0% | 13.1% | 10.1% | 15.3% |
Amortization of intangibles | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 76.0 |
EBIT | 3,313.0 | 2,682.0 | 2,204.0 | 4,405.0 | 3,947.0 | 4,391.0 | 3,164.0 | 4,420.0 |
EBIT margin | 17.4% | 15.0% | 13.2% | 12.8% | 11.0% | 13.1% | 10.1% | 15.0% |
Pre-tax income | 2,403.0 | 1,654.0 | 1,092.0 | 3,985.0 | 2,225.0 | 3,775.0 | 1,973.0 | 3,330.0 |
Income taxes | 349.0 | 38.0 | -7.0 | 774.0 | 118.0 | -126.0 | 753.0 | 1,073.0 |
Tax rate | 14.5% | 2.3% | | 19.4% | 5.3% | | 38.2% | 32.2% |
Earnings from continuing ops | 2,053.0 | 1,493.0 | 1,108.0 | 2,936.0 | 2,005.0 | 3,779.0 | 1,121.0 | 2,269.0 |
Earnings from discontinued ops | 117.0 | 213.0 | 855.0 | | | | | |
Net income | 2,170.0 | 1,706.0 | 1,963.0 | 2,936.0 | 2,005.0 | 3,779.0 | 1,121.0 | 2,269.0 |
Net margin | 11.4% | 9.5% | 11.8% | 8.5% | 5.6% | 11.3% | 3.6% | 7.7% |
|
Diluted EPS | $2.08 | $1.52 | $1.13 | $3.01 | $2.07 | $3.98 | $1.21 | $2.54 |
Shares outstanding (diluted) | 987.0 | 980.0 | 977.0 | 974.0 | 969.0 | 949.0 | 927.0 | 893.0 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|